LV12881B - NEW TREATMENT METHODS USING PHENETRIC SOLUTIONS - Google Patents
NEW TREATMENT METHODS USING PHENETRIC SOLUTIONS Download PDFInfo
- Publication number
- LV12881B LV12881B LVP-02-152A LV020152A LV12881B LV 12881 B LV12881 B LV 12881B LV 020152 A LV020152 A LV 020152A LV 12881 B LV12881 B LV 12881B
- Authority
- LV
- Latvia
- Prior art keywords
- carbon atoms
- alkyl
- hydrogen
- use according
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8384893A | 1993-06-28 | 1993-06-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
LV12881B true LV12881B (en) | 2002-11-20 |
Family
ID=22181084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LVP-02-152A LV12881B (en) | 1993-06-28 | 2002-08-15 | NEW TREATMENT METHODS USING PHENETRIC SOLUTIONS |
Country Status (15)
Country | Link |
---|---|
US (8) | US5916923A (fr) |
EP (3) | EP1738753B1 (fr) |
JP (2) | JPH0789851A (fr) |
KR (1) | KR100342762B1 (fr) |
AT (3) | ATE392893T1 (fr) |
AU (2) | AU6592994A (fr) |
CA (1) | CA2126305C (fr) |
CY (1) | CY2315B1 (fr) |
DE (3) | DE69434872T2 (fr) |
DK (3) | DK1153603T3 (fr) |
ES (3) | ES2174864T3 (fr) |
HK (1) | HK1038880B (fr) |
LV (1) | LV12881B (fr) |
PT (3) | PT1738753E (fr) |
SG (1) | SG47711A1 (fr) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6440457B1 (en) * | 1993-05-27 | 2002-08-27 | Alza Corporation | Method of administering antidepressant dosage form |
EP0667150B1 (fr) * | 1994-02-14 | 2002-12-11 | Wyeth | Venlafaxine et ses analogues pour induire une amélioration des fonctions cognitives |
PE57198A1 (es) * | 1996-03-25 | 1998-10-10 | American Home Prod | Formula de liberacion prolongada |
EP1331003B1 (fr) * | 1996-03-25 | 2015-08-26 | Wyeth LLC | Composition de venlafaxine à libération prolongée |
US6579899B1 (en) | 1998-07-16 | 2003-06-17 | Massachusetts Institute Of Technology | Composition for treatment of stress |
JP2002520353A (ja) * | 1998-07-16 | 2002-07-09 | マサチューセッツ インスティテュート オブ テクノロジー | ストレスの処置のための組成物 |
US6342533B1 (en) | 1998-12-01 | 2002-01-29 | Sepracor, Inc. | Derivatives of (−)-venlafaxine and methods of preparing and using the same |
CZ20013607A3 (cs) * | 1999-04-06 | 2002-06-12 | Sepracor Inc. | Farmaceutický prostředek |
US7291646B2 (en) | 1999-11-24 | 2007-11-06 | Wyeth | Ethers of O-desmethyl venlafaxine |
WO2001049679A1 (fr) * | 1999-12-30 | 2001-07-12 | H. Lundbeck A/S | Derives de 4-phenyle-1-piperazinyle, -piperidinyle et -tetrahydropyridyle |
US6572890B2 (en) * | 2000-01-13 | 2003-06-03 | Osmotica Corp. | Osmotic device containing venlafaxine and an anti-psychotic agent |
FR2807753B1 (fr) * | 2000-04-13 | 2002-06-07 | Adir | Nouveaux derives d'heterocycloalkylbenzocyclobutane et d'heteroarylbenzocyclobutane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
JP4220243B2 (ja) * | 2001-02-12 | 2009-02-04 | ワイス | O−デスメチル−ベンラファキシンの新規コハク酸塩 |
KR100421508B1 (ko) * | 2001-08-07 | 2004-03-09 | 김정한 | 항균 및 항진균 활성을 갖는 신규한 펜에틸아민 유도체와이의 염 |
CA2467593A1 (fr) * | 2001-12-05 | 2003-06-19 | Wyeth | Nouvelle forme cristalline polymorphe d'hydrochlorure de venlafaxine et methodes de preparation de ladite forme |
UA77234C2 (en) * | 2001-12-05 | 2006-11-15 | Wyeth Corp | Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants) |
AR039164A1 (es) | 2002-03-28 | 2005-02-09 | Synthon Bv | Sales de venlafaxina de baja solubilidad en agua |
AU2003226748A1 (en) * | 2002-03-28 | 2003-10-13 | Synthon B.V. | Compositions of venlafaxine base |
AR039163A1 (es) | 2002-03-28 | 2005-02-09 | Synthon Bv | Besilato de venlafaxina |
AU2003219117A1 (en) * | 2002-03-28 | 2003-10-13 | Synthon B.V. | Extended release venlafaxine formulations |
US20040002500A1 (en) * | 2002-06-28 | 2004-01-01 | Fabre Kramer Pharmaceutical, Inc. | Methods for treating attention deficit disorder |
PL377473A1 (pl) * | 2002-11-28 | 2006-02-06 | Themis Laboratories Private Limited | Sposób produkcji mikropeletek o przedłużonym uwalnianiu zawierających chlorowodorek wenlafaksyny |
US20070077301A1 (en) * | 2002-12-23 | 2007-04-05 | Meyer Glenn A | Venlafaxine osmotic device formulation |
WO2004075902A1 (fr) * | 2003-02-28 | 2004-09-10 | Amedis Pharmaceuticals Ltd. | Utilisation de derives de silicium de venlafaxine permettant de traiter ou de prevenir le psoriasis ou un trouble panique |
US20050048118A1 (en) * | 2003-07-25 | 2005-03-03 | Joan Cucala Escoi | Modified release venlafaxine hydrochloride tablets |
US7470435B2 (en) * | 2003-11-17 | 2008-12-30 | Andrx Pharmaceuticals, Llc | Extended release venlafaxine formulation |
US20050143350A1 (en) * | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
US20050142203A1 (en) * | 2003-12-30 | 2005-06-30 | Grant Heinicke | Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same |
US20050226923A1 (en) * | 2004-04-07 | 2005-10-13 | Gassert Chad M | Venlafaxine compositions in the form of microtablets |
US7776358B2 (en) * | 2004-07-22 | 2010-08-17 | Synthon Ip Inc. | Extended release venlafaxine besylate tablets |
US20060228413A1 (en) * | 2005-02-28 | 2006-10-12 | Penwest Pharmaceuticals Co. | Controlled release venlafaxine formulations |
MX2007013021A (es) * | 2005-04-22 | 2008-01-11 | Wyeth Corp | Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c. |
CA2604916A1 (fr) * | 2005-04-22 | 2006-11-02 | Wyeth | Derives de dihydrobenzofurane et utilisations associees |
AR056979A1 (es) * | 2005-04-22 | 2007-11-07 | Wyeth Corp | Derivados de dihidrobenzofuranos y usos de los mismos |
WO2006116149A1 (fr) * | 2005-04-22 | 2006-11-02 | Wyeth | Nouvelles associations therapeutiques pour le traitement ou la prevention de la depression |
JP2008538581A (ja) * | 2005-04-22 | 2008-10-30 | ワイス | {[(2r)−7−(2,6−ジクロロフェニル)−5−フルオロ−2,3−ジヒドロ−1−ベンゾフラン−2−イル]メチル}アミン塩酸塩の結晶形態 |
WO2007047972A2 (fr) * | 2005-10-19 | 2007-04-26 | Teva Pharmaceutical Industries Ltd. | Procede pour preparer de l'hydrochlorure de 1-[2-dimethylamino-(4-methoxyphenyl)ethyl]cyclohexanol tres pur |
SI1954669T1 (sl) * | 2005-12-01 | 2016-01-29 | Auspex Pharmaceuticals, Inc. | Substituirani fenetilamini s serotoninergično in / ali noradrenalinsko aktivnostjo |
AU2006322057A1 (en) | 2005-12-05 | 2007-06-14 | Wyeth | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols |
BRPI0709159A2 (pt) * | 2006-03-24 | 2011-06-28 | Wyeth Corp | combinações terapêuticas para o tratamento de depressão |
WO2007124045A2 (fr) * | 2006-04-20 | 2007-11-01 | Ampla Pharmaceuticals, Inc. | Potentialisation d'activité de récepteur mc4 |
US20080081067A1 (en) * | 2006-10-03 | 2008-04-03 | Gupta Manishkumar | Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof |
JP2010507667A (ja) * | 2006-10-25 | 2010-03-11 | ワイス エルエルシー | O−デスメチルベンラファキシンの単離されたヒドロキシおよびn−オキシド代謝産物および誘導体および治療方法 |
DK2125698T3 (en) * | 2007-03-15 | 2016-11-07 | Auspex Pharmaceuticals Inc | Deuterated d9-VENLAFAXINE |
WO2009023820A1 (fr) * | 2007-08-16 | 2009-02-19 | Cypress Biosciences, Inc. | Amélioration de la tolérabilité d'un antagoniste de sérotonine et d'un nsri, un snri ou un rima par leur utilisation combinée |
EP2222302A1 (fr) * | 2007-11-20 | 2010-09-01 | NeuroSearch A/S | Procédé de traitement des troubles d'hyperphagie |
KR100965527B1 (ko) * | 2008-05-08 | 2010-06-23 | 제일약품주식회사 | 신규(4-(2-(디메틸아미노)-1-(1-하이드록시사이클로헥실)에틸)페녹시)포스페이트 또는 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계질환 예방 및 치료용 조성물 |
CZ200969A3 (cs) * | 2009-02-06 | 2010-06-30 | Zentiva, K.S. | Nové soli desvenlafaxinu a zpusob jejich prípravy |
US9223364B2 (en) * | 2012-10-25 | 2015-12-29 | Inhon International Co., Ltd. | Heat dissipation control system for portable electrical device and control method thereof |
KR102132304B1 (ko) | 2020-02-17 | 2020-07-09 | 박광순 | 접이식 유아용 비데 |
RU2741226C1 (ru) * | 2020-09-08 | 2021-01-22 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РостГМУ Минздрава России) | Способ профилактики агрессии лиц с интернет-зависимостью |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4017637A (en) * | 1973-03-26 | 1977-04-12 | American Home Products Corporation | Benzylamine analgesics |
US3894051A (en) * | 1973-07-05 | 1975-07-08 | Colgate Palmolive Co | N-methylenedioxyphenylalkyl)-{62 -(alkyl)-disubstituted phenethylamines |
US4435449A (en) * | 1981-05-14 | 1984-03-06 | Burroughs Wellcome Co. | Treatment of minimal brain dysfunction (MBD) |
US4824868A (en) * | 1982-09-07 | 1989-04-25 | Ciba-Geigy Corporation | Propylamine derivatives useful for the treatment of dementia |
IE56324B1 (en) * | 1982-12-13 | 1991-06-19 | American Home Prod | Phenethylamine derivatives and intermediates therefor |
US4535186A (en) * | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
AU566673B2 (en) * | 1983-09-15 | 1987-10-29 | F. Hoffmann-La Roche Ag | Phenethylamine derivatives |
US4761501A (en) * | 1983-10-26 | 1988-08-02 | American Home Products Corporation | Substituted phenylacetamides |
US4611078A (en) * | 1983-10-26 | 1986-09-09 | American Home Products Corporation | Substituted phenylacetonitriles |
US4609758A (en) * | 1985-05-09 | 1986-09-02 | American Home Products Corporation | Phenoxyethylamine derivatives |
US4956388A (en) * | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
US5135947A (en) * | 1987-04-09 | 1992-08-04 | Eli Lilly And Company | 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors |
EP0386117B1 (fr) * | 1987-10-22 | 1999-01-07 | Massachusetts Institute Of Technology | Traitement du syndrome de phase luteale tardive ou premenstruelle |
US4996235A (en) * | 1987-11-25 | 1991-02-26 | Eli Lilly And Company | 3,4-diphenylbutanamines |
US5013761A (en) * | 1988-06-03 | 1991-05-07 | Eli Lilly And Company | Serotonin antagonists |
US5114976A (en) * | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
US5006525A (en) * | 1989-07-24 | 1991-04-09 | Eli Lilly And Company | Dopamine agonists method |
US5057515A (en) * | 1989-07-24 | 1991-10-15 | Eli Lilly And Company | Method for agonizing a dopamine receptor |
FI910897A (fi) * | 1990-02-28 | 1991-08-29 | Lilly Co Eli | Foerbaettringar roerande (s)-norfluoxetin. |
ZA912277B (en) * | 1990-03-29 | 1992-11-25 | Lilly Co Eli | The selective occupation of serotonin ic receptors |
EP1208838A3 (fr) * | 1991-11-15 | 2003-07-09 | Sepracor Inc. | Isomère pur de la S(+)fluoxétine |
US6440457B1 (en) * | 1993-05-27 | 2002-08-27 | Alza Corporation | Method of administering antidepressant dosage form |
TW460478B (en) * | 1997-08-15 | 2001-10-21 | Chugai Pharmaceutical Co Ltd | Phenethylamine derivatives |
-
1994
- 1994-06-13 ES ES94304252T patent/ES2174864T3/es not_active Expired - Lifetime
- 1994-06-13 ES ES06017469T patent/ES2304041T3/es not_active Expired - Lifetime
- 1994-06-13 AT AT06017469T patent/ATE392893T1/de not_active IP Right Cessation
- 1994-06-13 EP EP06017469A patent/EP1738753B1/fr not_active Revoked
- 1994-06-13 PT PT06017469T patent/PT1738753E/pt unknown
- 1994-06-13 DK DK01115854T patent/DK1153603T3/da active
- 1994-06-13 DK DK06017469T patent/DK1738753T3/da active
- 1994-06-13 DE DE69434872T patent/DE69434872T2/de not_active Expired - Lifetime
- 1994-06-13 PT PT01115854T patent/PT1153603E/pt unknown
- 1994-06-13 SG SG1996003989A patent/SG47711A1/en unknown
- 1994-06-13 AT AT94304252T patent/ATE213407T1/de active
- 1994-06-13 ES ES01115854T patent/ES2273764T3/es not_active Expired - Lifetime
- 1994-06-13 DK DK94304252T patent/DK0639374T3/da active
- 1994-06-13 DE DE69435095T patent/DE69435095T2/de not_active Revoked
- 1994-06-13 EP EP94304252A patent/EP0639374B1/fr not_active Expired - Lifetime
- 1994-06-13 DE DE69429895T patent/DE69429895T2/de not_active Expired - Lifetime
- 1994-06-13 AT AT01115854T patent/ATE342715T1/de active
- 1994-06-13 EP EP01115854A patent/EP1153603B1/fr not_active Revoked
- 1994-06-13 PT PT94304252T patent/PT639374E/pt unknown
- 1994-06-20 CA CA002126305A patent/CA2126305C/fr not_active Expired - Lifetime
- 1994-06-20 JP JP6137282A patent/JPH0789851A/ja active Pending
- 1994-06-23 AU AU65929/94A patent/AU6592994A/en not_active Abandoned
- 1994-06-27 KR KR1019940014801A patent/KR100342762B1/ko not_active IP Right Cessation
-
1997
- 1997-04-08 US US08/835,780 patent/US5916923A/en not_active Expired - Lifetime
-
1998
- 1998-03-10 AU AU58312/98A patent/AU5831298A/en not_active Abandoned
-
1999
- 1999-04-02 US US09/285,812 patent/US6310101B1/en not_active Expired - Lifetime
-
2001
- 2001-01-25 US US09/769,998 patent/US6444708B2/en not_active Expired - Fee Related
- 2001-06-27 US US09/892,363 patent/US6465524B2/en not_active Expired - Fee Related
- 2001-11-30 US US09/996,590 patent/US6555586B2/en not_active Expired - Fee Related
-
2002
- 2002-01-18 HK HK02100415.5A patent/HK1038880B/zh not_active IP Right Cessation
- 2002-08-15 LV LVP-02-152A patent/LV12881B/en unknown
-
2003
- 2003-02-04 CY CY0300009A patent/CY2315B1/xx unknown
- 2003-03-25 US US10/396,043 patent/US6730706B2/en not_active Expired - Fee Related
- 2003-11-25 US US10/721,629 patent/US20040110829A1/en not_active Abandoned
-
2005
- 2005-12-07 JP JP2005353812A patent/JP2006117689A/ja active Pending
-
2007
- 2007-08-20 US US11/841,636 patent/US20080176950A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LV12881B (en) | NEW TREATMENT METHODS USING PHENETRIC SOLUTIONS | |
US4018895A (en) | Aryloxyphenylpropylamines in treating depression | |
KR100236562B1 (ko) | 트라마돌 및 비-스테로이드성 소염제를 함유하는 조성물 | |
US4626549A (en) | Treatment of obesity with aryloxyphenylpropylamines | |
US5530013A (en) | Venlafaxine in the inducement of cognition enhancement | |
US4314081A (en) | Arloxyphenylpropylamines | |
FI100091B (fi) | Menetelmä kinapriilin värin stabiloimiseksi | |
HU204504B (en) | Process for producing phenoxy-bicyclo-amine derivatives and antidepressive pharmaceutical compositions containing them | |
US5506270A (en) | Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women | |
PT95760B (pt) | Utilizacao de sertralina na preparacao de um medicamento para o tratamento de perturbacoes relacionadas com a ansiedade | |
IE52170B1 (en) | (-)-n-methyl-3-(2-methylphenoxy)-3-phenylpropylamine,antidepressant | |
US20040019101A1 (en) | Methods of treating gastrointestinary and genitourinary pain disorders | |
PT80805B (pt) | Processo para a preparacao de derivados de fluorolilamina | |
IL43820A (en) | Pharmacological preparations for the treatment of deformed disabled, containing symptomatic aminophytic bronchodilators | |
EP0667150B1 (fr) | Venlafaxine et ses analogues pour induire une amélioration des fonctions cognitives | |
AU744990B2 (en) | New treatment using phenethylamine derivatives | |
US20080176951A1 (en) | Methods of treating gastrointestinary and genitourinary pain disorders | |
JPH078864B2 (ja) | 2―アルキル―3―ベンゾイルベンゾフラン | |
EP0053379A1 (fr) | Agent pour le traitement d'ulcères peptiques | |
JPH05271189A (ja) | インシュリン耐性被験者の高血圧症治療用n´−置換n−フェニルスルホニル尿素含有医薬組成物 | |
JP2005500344A (ja) | 3−アリールオキシ−3−フェニルプロパンアミンを用いた慢性疼痛の治療 |